This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

November 6–8, 2023 | Munich, GermanyNovember 14–15, 2023 | Digital Partnering

Verge Genomics


Verge has pioneered the industry's most advanced all-in-human, artificial intelligence powered drug discovery platform to unlock new drugs at scale for the biggest medical challenges of our time. Verge was born from the convergence of multiple technological forces, including human genomics, machine learning, biological engineering, and translational medicine, that are enabling us to decipher biology. Instead of using animal or cell models, we have built one of the world's largest proprietary multi-omics databases directly from human tissue. We use machine learning to map the complex causes of disease and develop those insights into proprietary drug candidates on our internal biology and chemistry platforms. Our first drug will enter the clinic this year for ALS and was discovered entirely from our platform. We are working on a dozen breakthrough opportunities on Parkinson's Disease, Frontotemporal Dementia, and other devastating diseases with no effective treatments to date.